home All News open_in_new Full Article

Sales of Novo Nordisk’s diabetes drugs including Ozempic slow sharply

Fierce competition and threat of Trump tariffs lead to Danish company cutting costsSales of Novo Nordisk’s injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of US tariffs, prompting it to cut costs and sharpen its commercial focus.The Danish drugmaker, whose booming sales of GLP-1 diabetes and obesity drugs in recent years had turned it into Europe’s most valuable company, has lost $95bn (£71.5bn) in market value since cutting its full-year sales forecast last week. Continue reading...


today 9 d. ago attach_file Events

attach_file Events
attach_file Events
attach_file Events
attach_file Events
attach_file Economics
attach_file Events


ID: 477071617
Add Watch Country

arrow_drop_down